LDS/Medical Tests/Hereditary Erythrocytosis Gene Mutation Panel, NGS

Hereditary Erythrocytosis Gene Mutation Panel, NGS

Hereditary erythrocytosis (ECYT) is an inherited condition characterized by an abnormally increased number of red blood cells (erythrocytes) despite normal levels of tissue oxygenation. Signs and symptoms of familial erythrocytosis are due to blood hyperviscosity and include headaches, dizziness, nosebleeds, and shortness of breath. Patients with erythrocytosis are also at increased risk of both arterial and venous thrombosis. Restriction of blood flow to the essential organs and tissues (particularly the heart, lungs, or brain) can cause life-threatening complications such as a heart attack or stroke.

The inheritance pattern of hereditary erythrocytosis depends on the gene involved. Autosomal dominant Hereditary erythrocytosis is related to mutations in EPOR, EGLN1, or EPAS1 genes while mutations in the VHL gene are inherited in an autosomal recessive pattern. This condition is rare, and its prevalence is unknown. The EPOR gene encodes for the erythropoietin receptor and mutations in this gene result in prolonged intracellular signaling and red cell production even when erythropoietin levels are low.

Mutations in one of the genes involved with oxygen-sensing pathway proteins (VHL, EGLN1, and EPAS1) may result in inappropriately increased erythropoietin levels which drive the bone marrow to produce excessive numbers of red cells. The EPAS1 gene codes for a protein that is one of the components of the hypoxia-inducible factor (HIF) protein complex. HIF activates genes that encode erythropoietin. VHL and EGLN1 genes produce proteins that control HIF and indirectly regulate erythropoietin. Hereditary erythrocytosis due to VHL gene mutations is known as ECYT2, due to EGLN1 gene is called ECYT3 and due to EPAS1 gene is known as ECYT4.

Panel Components:

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: ANK1, BPGM, CALR, EGLN1, EPAS1, EPB41, EPB42, EPOR, HBA1, HBA2, HBB, HIF1A, JAK2, KCNN4, PIEZO1, PKLR, RHAG, SH2B3, SLC4A1, SPTA1, SPTB, TET2, TET3, VHL associated with hereditary erythrocytosis.

  • Diagnostic confirmation of hereditary erythrocytosis in symptomatic individuals
  • For the risk assessment of asymptomatic family members of a proband diagnosed with hereditary erythrocytosis
  • To differentiate the hereditary erythrocytosis from acquired (non-genetic) forms of erythrocytosis (eg polycythemia vera)

Positive; At least one known pathogenic variant or mutation associated with hereditary erythrocytosis should be detected in the tested genes.

Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants

Negative; No pathogenic variant detected in the tested genes.

Negative for pathogenic variant, deletions, and duplications in the tested genes

Polymerase Chain Reaction (PCR) Amplification/Sanger Sequence Analysis, Next-Generation (NGS)/Massively parallel sequencing (MPS).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
CBC with differential, erythropoietin (EPO) level, bone marrow aspiration and analysis, Hemoglobin oxygen affinity.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login